Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
25 /100
LOW RISK
Score updated Jul 28, 2026

ZVRA — Zevra Therapeutics, Inc. Dilution Risk Tracker

Track ZVRA dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ZVRA — Get alerts when the score changes →

As of July 28, 2026, Zevra Therapeutics, Inc. (ZVRA) has a DilutionWatch DilutionScore of 25/100, rated LOW dilution risk. Zevra Therapeutics, Inc. has a market capitalization of $685.14M, 59.12M shares outstanding, 149 institutional holders tracked. Key dilution vectors include approximately 55 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
0
📊 Float Risk
10
⚠️ Warrant Exposure
40
🔄Convertible Debt

Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for ZVRA.
🔔 Track ZVRA — Get forecast alerts →

Market Data

Market Cap$685.14M
Shares Outstanding59.12M
Float54.96M
Cash$101.43M
Debt$1.15M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 27.1% shares (2026Q1 vs prior)
149 institutional holders · 54.20M shares
#1 Woodline Partners LP 6.90M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 4.94M shares
#3 BlackRock, Inc. 4.46M shares
+ 17 more holders Sign up free to view →

Short Interest

Short Interest7.80M
Days to Cover5.4
% of Float14.2%
FINRA data as of Jul 15, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31
xbrl XBRL CONVERTIBLE 2021-12-31
Full SEC filing analysis available with free account

Recent News

No recent news

What This Means for ZVRA Shareholders

Zevra Therapeutics, Inc. (ZVRA) has a DilutionScore of 25/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 28, 2026.

DilutionWatch's EDGAR monitoring for ZVRA shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for ZVRA in real-time, scanning EDGAR every 60 seconds. The DilutionWatch shows real-time score changes for ZVRA alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Understanding ZVRA's Dilution Risk Factors

Primary Risk Drivers

The two highest-risk factors for Zevra Therapeutics are Offering Ability and Cash Runway. Offering Ability scores at a level indicating significant potential for new capital raises, which could dilute existing shareholders. This factor is particularly concerning because it reflects the company’s capacity to issue new shares without shareholder approval or pre-emptive rights. The Cash Runway score of zero means the company has no immediate cash concerns, but this also implies that the firm may be relying on future funding rounds to sustain operations, increasing the risk of dilution through equity issuance.

Factors Currently Not a Concern

Float Risk and Warrant Exposure are currently low, indicating minimal risk from large block sales or warrant conversions. Float Risk at a low level suggests that a small portion of shares is available for trading, limiting potential market impact from sudden selling. Warrant Exposure is similarly low, meaning the company’s outstanding warrants do not pose an immediate threat to share count. However, any material increase in the number of warrants issued or a significant drop in warrant strike prices could elevate this risk. Additionally, Convertible Note Risk remains manageable, but a large conversion event or issuance of new convertible debt would raise concerns.

SEC Filings to Watch

Several SEC filings are critical for monitoring ZVRA’s dilution profile. An S-3 registration statement signals potential large-scale equity offerings, which could significantly increase share count. A 424B5 filing often accompanies such offerings and provides details on the terms of new securities. An 8-K Item 1.01 reports material events like new equity issuances or changes in capital structure. A 10-Q filing may disclose updated financials or changes in outstanding shares that could indicate upcoming dilution events.

How Dilution Happens

Dilution occurs when the company issues additional shares, increasing the total number of shares outstanding. If Offering Ability is high, it implies that new equity can be raised easily, potentially through private placements or public offerings. As cash runway nears zero, the company may need to raise capital, and this often involves issuing new shares. Existing shareholders see their ownership percentage decrease as more shares are created, even if the total value of their holdings remains constant. Convertible notes and warrants can also convert into equity, further diluting existing shareholdings.

What Would Make This Worse

A significant deterioration in risk would occur if the company begins issuing convertible debt or warrants with low strike prices, or if it files an S-3 offering. An 8-K Item 1.01 announcement of a major capital raise or a large-scale conversion of convertible notes could trigger substantial dilution. If the Cash Runway score increases from zero to a higher level, it may indicate that the company is running out of cash and will need to issue more shares to survive, increasing dilution risk.

Key Insight

Low scores on all factors indicate safer conditions for investors, with zero-risk levels signaling no immediate concern for dilution.

How to Monitor ZVRA for Dilution Risk

What This Risk Level Means

For a small-cap operating company like Zevra Therapeutics, a low dilution risk score indicates that the firm is currently managing its capital structure in a relatively conservative manner. With a diluted equity base and limited exposure to high-risk financing mechanisms, the company’s ability to raise capital without significantly diluting existing shareholders is strong. This is particularly important for small-cap firms, which often rely on external funding to sustain operations and growth. The low risk score suggests that ZVRA has not recently engaged in large equity offerings or issued significant warrants or convertible notes that could dilute shareholder value. As an operating company with limited financial complexity, it is less likely to be using aggressive capital-raising strategies that might threaten current investors.

What Typically Happens Next

Companies at this profile often move through a series of financing events over time. Common next steps include shelf registrations or ATM programs, which allow for flexible capital raising without immediate dilution impact. Warrant exercises and convertible note conversions are also typical as companies approach key milestones or funding rounds. Given the elevated factors present — such as Offering Ability, Warrant Exposure, and Convertible Note Risk — ZVRA may be preparing to enter a phase of increased fundraising activity. Monitoring these events is critical, particularly in the context of Shelf & ATM Monitor, which tracks such capital-raising tools for small-cap firms.

Monitoring Playbook

To effectively track ZVRA’s dilution risk using DilutionWatch, set up a watchlist and review the DilutionScore weekly. Pay attention to changes in Offering Ability, Warrant Exposure, and Convertible Note Risk scores. A spike in any of these components should trigger an immediate investigation into recent SEC filings. Additionally, monitor for new equity offerings or warrant exercises that could alter the capital structure. When thresholds are hit — such as a score exceeding 40/100 in any factor — take action by reviewing relevant 8-Ks and S-1 filings to assess potential dilutive impact.

Early Warning Signals

Several specific signals indicate worsening dilution risk. First, the filing of a shelf registration or ATM program is a strong early warning sign, as it often precedes future equity issuance. Second, an increase in warrant exposure or convertible note risk scores — especially if they exceed 45/100 — signals growing reliance on dilutive financing mechanisms. Third, a sudden spike in Offering Ability score may indicate that the company is preparing to raise capital through new equity offerings.

What a Positive Resolution Looks Like

A positive shift in ZVRA’s profile would occur if the company raises new capital through non-dilutive means such as debt financing or strategic partnerships. Alternatively, a reduction in outstanding warrants or convertible notes — such as their expiration or conversion into equity — could improve the risk score. Another favorable development is a decrease in Offering Ability, suggesting that the company is not actively preparing for large equity offerings.

Watch For

Any new SEC filings indicating an upcoming equity offering or warrant exercise, especially if they occur within 6 months of current reporting.

Full SEC filing analysis available with free account  →
Track ZVRA Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ZVRA — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for ZVRA
ZVRA FDA Catalyst Timeline & Biotech Grade — BiotechSignsZVRA Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.